| Literature DB >> 24649374 |
Anders Ståhlberg1, Pierre Aman2, Linda Strömbom1, Neven Zoric3, Alfredo Diez2, Olle Nilsson4, Mikael Kubista5, Börje Ridell2.
Abstract
In healthy humans, 60-70% of the B lymphocytes produce kappa light chains, while the remaining cells produce lambda light chains. Malignant transformation and clonal expansion of B lymphocytes lead to an altered kappa : lambda expression ratio, which is an important diagnostic criteria of lymphomas. Here, we compared three methods for clonality determination of suspected B cell lymphomas. Tumor biopsies from 55 patients with B cell malignancies, 5 B-lymphoid tumor cell lines, and 20 biopsies from patients with lymphadenitis were analyzed by immunohistochemistry, flow cytometry, and reverse transcription quantitative real-time PCR. Clonality was determined by immunohistochemistry in 52/53 cases, flow cytometry in 30/39 cases, and reverse transcription quantitative real-time PCR in 33/55 cases. In conclusion, immunohistochemistry was superior to flow cytometry and reverse transcription quantitative real-time PCR for clonality identification. Flow cytometry and reverse transcription quantitative real-time PCR analysis has complementary values. In a considerable number of cases tumor cells produced both kappa and lambda light chain transcripts, but only one type of light chain peptide was produced.Entities:
Year: 2014 PMID: 24649374 PMCID: PMC3932212 DOI: 10.1155/2014/796210
Source DB: PubMed Journal: ISRN Oncol ISSN: 2090-5661
Detailed patient information.
| Sample ID | Classification | Gender | Age | FC | IHC | RT-qPCR |
|---|---|---|---|---|---|---|
| 111 | CLL | F | 70 | ND | Lambda | Lambda |
| 112 | CLL | F | 82 | ND | Lambda | MNP |
| 113 | CLL | M | 58 | Lambda | Lambda | Lambda |
| 115 | CLL | F | 61 | Lambda | Lambda | Lambda |
| 116 | CLL | F | 57 | Kappa | Kappa | Kappa |
| 117 | CLL | F | 75 | Kappa | Kappa | Kappa |
| 118 | CLL | F | 85 | Kappa | Kappa | Kappa |
| 119 | CLL | F | 48 | ND | Lambda | Lambda |
| 131 | CLL | M | 72 | ND | Lambda | Lambda |
| 132 | CLL | F | 59 | ND | Lambda | Lambda |
| 145 | CLL | F | 76 | Kappa | Kappa | MNP |
| 146 | CLL | M | 46 | Lambda | Lambda | Lambda |
| 147 | CLL | F | 74 | Kappa | Kappa | Kappa |
| 149 | CLL | F | 76 | Kappa | Kappa | MNP |
| 189 | CLL | F | 65 | Kappa | Kappa | MNP |
| 191 | CLL | M | 60 | Lambda | Lambda | Lambda |
| 120 | DLBL | M | 80 | ND | Kappa | MNP |
| 121 | DLBL | M | 81 | ND | Kappa | Kappa |
| 123 | DLBL | M | 64 | Kappa | Kappa | Kappa |
| 124 | DLBL | F | 77 | Kappa | Kappa | Kappa |
| 125 | DLBL | M | 57 | ND | MNP | Lambda |
| 126 | DLBL | M | 70 | Lambda | Lambda | Lambda |
| 127 | DLBL | M | 70 | Kappa | Kappa | Kappa |
| 129 | DLBL | M | 58 | ND | Kappa | MNP |
| 133 | DLBL | M | 72 | MNP | Lambda | MNP |
| 135 | DLBL | F | 75 | MNP | Kappa | Kappa |
| 136 | DLBL | F | 78 | ND | Kappa | MNP |
| 137 | DLBL | M | 70 | Kappa | Kappa | Kappa |
| 138 | DLBL | M | 72 | ND | Kappa | MNP |
| 139 | DLBL | M | 33 | Kappa | Kappa | Kappa |
| 140 | DLBL | F | 78 | Kappa | Kappa | kappa |
| 153 | DLBL | M | 19 | ND | Kappa | Kappa |
| 156 | DLBL | M | 58 | Kappa | Kappa | Kappa |
| 182 | DLBL | F | 75 | MNP | Kappa | MNP |
| 184 | DLBL | M | 55 | Kappa | Kappa | Kappa |
| 186 | DLBL | F | 66 | Kappa | Kappa | Kappa |
| 157 | FL | F | 54 | Kappa | Kappa | MNP |
| 158 | FL | F | 51 | ND | Kappa | MNP |
| 159 | FL | M | 77 | ND | Kappa | MNP |
| 160 | FL | F | 60 | ND | Lambda | MNP |
| 161 | FL | M | 70 | Lambda | Lambda | MNP |
| 162 | FL | M | 69 | Kappa | Kappa | Kappa |
| 163 | FL | M | 52 | Kappa | Kappa | Kappa |
| 164 | FL | M | 53 | ND | Kappa | Kappa |
| 165 | FL | F | 59 | Kappa | Kappa | MNP |
| 166 | FL | M | 61 | MNP | Kappa | MNP |
| 167 | FL | F | 30 | MNP | Lambda | MNP |
| 168 | FL | M | 51 | MNP | Kappa | Kappa |
| 208 | FL | F | 83 | MNP | ND | MNP |
| 209 | FL | F | 55 | Lambda | Lambda | Lambda |
| 210 | FL | F | 46 | MNP | Kappa | MNP |
| 211 | FL | M | 64 | Lambda | ND | MNP |
| 204 | MCL | M | 61 | Lambda | Lambda | Lambda |
| 206 | MCL | F | 78 | Kappa | Kappa | Kappa |
| 207 | MCL | F | 70 | Kappa | Kappa | MNP |
| 101 | LA | F | 62 | ND | MNP | Control |
| 102 | LA | M | 25 | ND | MNP | Control |
| 103 | LA | M | 25 | ND | MNP | Control |
| 104 | LA | M | 16 | ND | MNP | Control |
| 105 | LA | F | 58 | ND | MNP | Control |
| 106 | LA | M | 59 | ND | MNP | Control |
| 107 | LA | M | 41 | ND | MNP | Control |
| 108 | LA | M | 7 | ND | MNP | Control |
| 109 | LA | F | 33 | ND | MNP | Control |
| 110 | LA | F | 28 | ND | MNP | Control |
| 192 | LA | F | 1 | MNP | MNP | Control |
| 193 | LA | F | 40 | MNP | MNP | Control |
| 194 | LA | M | 28 | MNP | MNP | Control |
| 195 | LA | M | 20 | MNP | MNP | Control |
| 196 | LA | M | 13 | MNP | MNP | Control |
| 197 | LA | M | 30 | MNP | MNP | Control |
| 198 | LA | F | 10 | MNP | MNP | Control |
| 199 | LA | F | 58 | MNP | MNP | Control |
| 200 | LA | M | 49 | MNP | MNP | Control |
| 201 | LA | F | 57 | MNP | MNP | Control |
CLL: chronic lymphocytic leukemia; DLBL: diffuse large B cell lymphoma; FL: follicular lymphoma; LA: lymphadenitis; F: female; M: male; MNP: monoclonality not proven; FC: flow cytometry; IHC: immunohistochemistry.
Monoclonal populations detected in lymphoma and lymphadenitis biopsiesa.
| RT-qPCR | FC | IHC | |
|---|---|---|---|
| CLL | 12/16 | 11/11 | 16/16 |
| DLBL | 14/20 | 10/13 | 19/20 |
| FL | 5/16 | 6/12 | 14/14 |
| MCL | 2/3 | 3/3 | 3/3 |
| CLL/lymphoma total | 33/55 | 30/39 | 52/53 |
| LA | 0/20 | 0/10 | 0/20 |
aNumber of samples with clonality proven/total number of samples is shown. CLL: chronic lymphocytic leukemia; DLBL: diffuse large B cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; LA: lymphadenitis (polyclonal control).
Figure 1Comparison of IGKC : IGLC ratio between FC and RT-qPCR. The Pearson correlation coefficient is 0.65 (P < 0.01). The FC ratio refers to cell number, while the RT-qPCR ratio refers to transcript number. The areas where no monoclonality (MNP) could be proven are shown as dashed lines. Grey square, lymphadenitis; stars, diffuse large B cell lymphoma; triangles, chronic lymphocytic leukemia; dot, follicular lymphoma; circles, mantle cell lymphoma; κ, IGKC; λ, IGLC.
Figure 2Immunohistochemistry of sample 165. The follicular lymphoma sample 165 was stained for (a) IGKC and (b) IGLC. Using RT-qPCR no clonality could be proven for this IGKC IHC positive sample.
RT-qPCR data for 5 B-lymphoid tumor cell lines.
| Cellinje | Kappa Cq | Lambda Cq | Kappa noRT Cq | Lambda noRT Cq | mRNA expression | IHC |
|---|---|---|---|---|---|---|
| U698 | 10.3 | 13.8 | 27 | 23.5 | Kappa > Lambda | Kappa |
| DG75 | 10.4 | 15.9 | 25.2 | 24.2 | Kappa > Lambda | Kappa |
| MC116 | 34.8 | 10.4 | Not detected | 23.5 | Lambda only | Lambda |
| RPMI8226 | 12.2 | 14.4 | 25.1 | 22.2 | Kappa > Lambda | Lambda |
| CCRF-SB | 12.3 | 11.2 | 26.7 | 24.4 | Lambda </ | Kappa |
| Neg. control | >33 | ~30 |
Cq: cycle of quantification (log transcript numbers); noRT: samples without reverse transcriptase; IHC: immunohistochemistry.